// App-Quantinova.ai

1465 : Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada

Researchers

Presenter

  • J Foo

Principal Investigators

  • JM Rodriguez Heredia

  • C Polanco Snchez

  • M Mtibaa

  • KH Herrmann

  • E Alemao

  • R Postema

  • C Baerwald

Medical Centers

  • Mapi Group, Houten, Netherlands

  • Hospital Universitario de Getafe, Getafe, Spain

  • Bristol-Myers Squibb, Madrid, Spain

  • Bristol-Myers Squibb, Montreal, QC, Canada

  • Bristol-Myers Squibb, Munich, Germany

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Bristol-Myers Squibb, Uxbridge, United Kingdom

  • University Hospital, Department of Internal Medicine, Rheumatology Unit, Leipzig, Germany

Locations

  • Netherlands

  • Spain

  • Canada

  • Germany

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • Abatacept

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved